De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Joinn Laboratories(China)Co.Ltd Beheer

Beheer criteriumcontroles 3/4

De CEO Joinn Laboratories(China)Co.Ltd's is Dapeng Gao, benoemd in Mar2013, heeft een ambtstermijn van 11.58 jaar. bezit rechtstreeks 0.039% van de aandelen van het bedrijf, ter waarde CN¥ 4.83M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 11.8 jaar en 5.8 jaar.

Belangrijke informatie

Dapeng Gao

Algemeen directeur

CN¥1.9m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	11.6yrs
Eigendom CEO	0.04%
Management gemiddelde ambtstermijn	11.8yrs
Gemiddelde ambtstermijn bestuur	5.8yrs

Recente managementupdates

Recent updates

Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) 28% Share Price Surge Not Quite Adding Up

Oct 01

Joinn Laboratories(China)Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03

Joinn Laboratories(China)Co.Ltd (SHSE:603127) Is Reducing Its Dividend To CN¥0.16

Jul 28

Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) Analysts Just Cut Their EPS Forecasts Substantially

Apr 08

There May Be Reason For Hope In Joinn Laboratories(China)Co.Ltd's (SHSE:603127) Disappointing Earnings

Apr 04

Analyse CEO-vergoeding

Hoe is Dapeng Gao's beloning veranderd ten opzichte van Joinn Laboratories(China)Co.Ltd's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	CN¥137m
Mar 31 2024	n/a	n/a	-CN¥63m
Dec 31 2023	CN¥2m	n/a	CN¥397m
Sep 30 2023	n/a	n/a	CN¥770m
Jun 30 2023	n/a	n/a	CN¥794m
Mar 31 2023	n/a	n/a	CN¥1b
Dec 31 2022	CN¥2m	n/a	CN¥1b
Sep 30 2022	n/a	n/a	CN¥941m
Jun 30 2022	n/a	n/a	CN¥775m
Mar 31 2022	n/a	n/a	CN¥589m
Dec 31 2021	CN¥2m	CN¥644k	CN¥557m
Sep 30 2021	n/a	n/a	CN¥419m
Jun 30 2021	n/a	n/a	CN¥379m
Mar 31 2021	n/a	n/a	CN¥389m
Dec 31 2020	CN¥2m	CN¥573k	CN¥315m
Sep 30 2020	n/a	n/a	CN¥253m
Jun 30 2020	n/a	n/a	CN¥237m
Mar 31 2020	n/a	n/a	CN¥194m
Dec 31 2019	CN¥1m	CN¥483k	CN¥187m

Compensatie versus markt: De totale vergoeding ($USD 270.89K ) Dapeng } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de CN markt ($USD 173.94K ).

Compensatie versus inkomsten: De vergoeding van Dapeng is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Dapeng Gao (42 yo)

11.6yrs

Tenure

CN¥1,901,300

Compensatie

Mr. Dapeng Gao is the Executive Director of Joinn Laboratories (China) Co.,Ltd. since August 2020 and has been its General Manager since January 28, 2019 and Joint Secretary since January 2019 and August 2...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Yuxia Feng	Founder & Chairman	11.8yrs	CN¥3.21m	22.76% CN¥ 2.6b
Dapeng Gao	GM, Secretary to the Board	11.6yrs	CN¥1.90m	0.039% CN¥ 4.5m
Conglin Zuo	Co-Founder & Vice Chairman	11.8yrs	CN¥1.90m	1.92% CN¥ 221.3m
Aishui Yu	Chief Financial Officer	5.3yrs	CN¥1.26m	0.0046% CN¥ 535.1k
Dalin Yao	Senior Vice GM	12.7yrs	CN¥1.86m	0.010% CN¥ 1.2m
Jingliang Gu	Vice GM & Head of Sales Department	13.8yrs	CN¥1.86m	0.037% CN¥ 4.2m
Yunxia Sun	Vice GM & Executive Director	11.8yrs	CN¥1.86m	0.37% CN¥ 42.4m

11.8yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 603127 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 11.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yuxia Feng	Founder & Chairman	11.8yrs	CN¥3.21m	22.76% CN¥ 2.6b
Dapeng Gao	GM, Secretary to the Board	11.1yrs	CN¥1.90m	0.039% CN¥ 4.5m
Conglin Zuo	Co-Founder & Vice Chairman	11.8yrs	CN¥1.90m	1.92% CN¥ 221.3m
Dalin Yao	Senior Vice GM	5.8yrs	CN¥1.86m	0.010% CN¥ 1.2m
Yunxia Sun	Vice GM & Executive Director	5.8yrs	CN¥1.86m	0.37% CN¥ 42.4m
Ye Li	Supervisor	11.8yrs	geen gegevens	0.014% CN¥ 1.6m
Mingcheng Sun	Independent Non-Executive Director	5.8yrs	CN¥150.00k	geen gegevens
Yonggong Zhai	Independent Non-Executive Director	5.8yrs	CN¥150.00k	geen gegevens
Xiaojie Ou	Independent Non-Executive Director	5.8yrs	CN¥150.00k	geen gegevens
Fan Zhang	Independent Non-Executive Director	3.7yrs	CN¥162.00k	geen gegevens
Yingjun He	Chairman of the Supervisory Board	1.9yrs	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 603127 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

Joinn Laboratories(China)Co.Ltd Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Joinn Laboratories(China)Co.,Ltd., Annual General Meeting, Jun 20, 2024

GM, Secretary to the Board recently sold CN¥2.5m worth of stock

Co-Founder & Vice Chairman recently sold CN¥6.2m worth of stock

Vice GM & Executive Director recently sold CN¥6.9m worth of stock

Co-Founder & Vice Chairman recently sold CN¥12m worth of stock

Co-Founder & Vice Chairman recently sold CN¥12m worth of stock

Recent updates

Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) 28% Share Price Surge Not Quite Adding Up

Joinn Laboratories(China)Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New minor risk - Share price stability

Consensus EPS estimates fall by 27%

Joinn Laboratories(China)Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Joinn Laboratories(China)Co.Ltd (SHSE:603127) Is Reducing Its Dividend To CN¥0.16

Dividend of CN¥0.16 announced

Joinn Laboratories(China)Co.,Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Joinn Laboratories(China)Co.,Ltd., Annual General Meeting, Jun 20, 2024

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) Analysts Just Cut Their EPS Forecasts Substantially

There May Be Reason For Hope In Joinn Laboratories(China)Co.Ltd's (SHSE:603127) Disappointing Earnings

Consensus revenue estimates fall by 19%

Joinn Laboratories(China)Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Consensus EPS estimates fall by 19%

Price target decreased by 8.6% to CN¥22.33

Investor sentiment improves as stock rises 19%

Now 23% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 19%

Now 23% undervalued after recent price drop

Now 23% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023

Price target decreased by 7.2% to CN¥25.92

Price target decreased by 7.3% to CN¥28.66

Now 20% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

GM, Secretary to the Board recently sold CN¥2.5m worth of stock

Consensus EPS estimates fall by 27%

Now 20% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 700%

New minor risk - Share price stability

Co-Founder & Vice Chairman recently sold CN¥6.2m worth of stock

Vice GM & Executive Director recently sold CN¥6.9m worth of stock

Consensus EPS estimates increase by 24%

Consensus EPS estimates fall by 10%

Price target decreased by 11% to CN¥33.30

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 13% to CN¥37.55

Now 25% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2023

Price target decreased by 8.7% to CN¥57.93

Co-Founder & Vice Chairman recently sold CN¥12m worth of stock

Co-Founder & Vice Chairman recently sold CN¥12m worth of stock

Co-Founder & Vice Chairman recently sold CN¥8.9m worth of stock

Joinn Laboratories (China) Co.,Ltd. Declares Final Dividend for the Year Ended December 31, 2022, Payable on 20 July 2023

Joinn Laboratories(China)Co.,Ltd., Annual General Meeting, Jun 09, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 7.4% to CN¥70.19

Price target increased by 7.4% to CN¥76.57

Insider recently sold CN¥56m worth of stock

JOINN Laboratories (China) Co., Ltd. Provides Revenue Guidance for the Period January 1, 2022 to December 31, 2022

Insider recently sold CN¥57m worth of stock

Co-Founder & Vice Chairman recently sold CN¥31m worth of stock

Insider recently sold CN¥30m worth of stock

Co-Founder & Vice Chairman recently sold CN¥65m worth of stock

Price target decreased to CN¥71.30

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued after recent price drop

Co-Founder & Vice Chairman recently sold CN¥180m worth of stock

Price target increased to CN¥86.02

Insider recently sold CN¥60m worth of stock

Now 21% undervalued after recent price drop

Price target decreased to CN¥74.80

Second quarter 2022 earnings released: EPS: CN¥0.46 (vs CN¥0.11 in 2Q 2021)

Joinn Laboratories(China)Co.,Ltd. SHS (China) to Be Deleted from OTC Equity